Cardiac Involvement in Limited Systemic Sclerosis: Non-invasive Assessment in Asymptomatic Patients

1999 ◽  
Vol 18 (2) ◽  
pp. 136-139 ◽  
Author(s):  
R. Handa ◽  
K. Gupta ◽  
A. Malhotra ◽  
P. Jain ◽  
P. K. Kamath ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Non Invasive ◽  
Asymptomatic Patients ◽  
Limited Systemic Sclerosis

scholarly journals Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis

1996 ◽  
Vol 39 (7) ◽  
pp. 1138-1145 ◽  
Author(s):  
Jaume Candell-Riera ◽  
Lluís Armadans-Gil ◽  
Carmen-Pilar Simeón ◽  
Joan Castell-Conesa ◽  
Vicent Fonollosa-Pla ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Limited Systemic Sclerosis ◽  
Noninvasive Assessment

Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis

2008 ◽  
Vol 27 (8) ◽  
pp. 991-997 ◽  
Author(s):  
Michał Ciurzyński ◽  
Piotr Bienias ◽  
Barbara Lichodziejewska ◽  
Katarzyna Kurnicka ◽  
Agnieszka Szewczyk ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Functional Evaluation ◽  
Non Invasive

Early Detection of Cardiac Involvement in Systemic Sclerosis Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction

2010 ◽  
Vol 37 (5) ◽  
pp. 993-999 ◽  
Author(s):  
THEODOROS DIMITROULAS ◽  
GEORGIOS GIANNAKOULAS ◽  
KLIO PAPADOPOULOU ◽  
HARALAMBOS KARVOUNIS ◽  
HARA DIMITROULA ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Endothelial Dysfunction ◽  
Cardiac Function ◽  
Doppler Echocardiography ◽  
Cardiac Involvement ◽  
Tissue Doppler ◽  
Left Ventricular ◽  
Tissue Doppler Echocardiography ◽  
Motion Velocity ◽  
Asymptomatic Patients

Objective.Cardiopulmonary complications are common in patients with systemic sclerosis (SSc). We assessed cardiac involvement in patients with SSc using echocardiography and investigated the association of N-terminal pro-brain natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) with echocardiographic measures of myocardial function in sera of patients with SSc who had no symptoms of heart failure.Methods.We prospectively studied 52 patients with SSc (mean age 55.7 ± 10.1 yrs, 51 women), with conventional and tissue-Doppler echocardiography. Plasma NT-proBNP and ADMA levels were measured in all patients. Data were compared with those obtained from 25 healthy controls comparable for age and sex.Results.Patients with SSc had impaired left ventricular (LV) and right ventricular diastolic function expressed by inverted ratio of peak early to peak late transmitral (Mit E/A) and transtricuspid velocity and increased left atrial diameter compared with controls. Peak systolic mitral lateral annular motion velocity and peak early diastolic mitral lateral annular motion velocity (LV Em) were lower, while LV E/Em ratio was higher, in patients with SSc compared to controls. ADMA was significantly related with LV Em and E/Em ratio. NT-proBNP was associated with Mit E, Mit E/A ratio and mitral deceleration time. Significant correlation was also observed between NT-proBNP and ADMA levels.Conclusion.Depressed cardiac function is common, even in asymptomatic patients with SSc. NT-proBNP and ADMA are significantly correlated with echocardiographic abnormalities, providing a potent link for cardiac function, neuroendocrine derangement, and endothelial dysfunction in patients with SSc who have cardiac disease.

scholarly journals Non-invasive assessment of early cardiac involvement in systemic sclerosis.

1985 ◽  
Vol 61 (718) ◽  
pp. 679-684 ◽  
Author(s):  
G. S. Butrous ◽  
P. M. Dowd ◽  
J. Milne ◽  
D. S. Dymond ◽  
J. Caplin ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Non Invasive

scholarly journals 1151 Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis

2006 ◽  
Vol 7 ◽  
pp. S204-S204
Author(s):  
M CIURZYNSKI ◽  
P BIENIAS ◽  
M GLINSKAWIELOCHOWSKA ◽  
B LICHODZIEJEWSKA ◽  
K KURNICKA ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Functional Evaluation ◽  
Non Invasive

scholarly journals THU0351 MUSCLE INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ANTI-PM/SCL+ ANTIBODIES IS ASSOCIATED WITH CARDIAC AND PULMONARY INVOLVEMENT. ANALYSIS OF THE MULTICENTRE EUSTAR COHORT.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 407.1-407
Author(s):  
M. G. Lazzaroni ◽  
S. Zingarelli ◽  
P. Airò ◽  
Y. Allanore ◽  
O. Distler
Keyword(s):  
Systemic Sclerosis ◽  
Cardiac Involvement ◽  
Severe Disease ◽  
Disease Onset ◽  
Pulmonary Involvement ◽  
Left Ventricular ◽  
Research Support ◽  
Muscle Involvement ◽  
Group A ◽  
Tendon Friction Rubs

Background:Anti-PM/Scl antibodies positivity has been associated with frequent skeletal muscle involvement in patients with Systemic Sclerosis (SSc) in different studies, including the EUSTAR cohort (1). Moreover, although myositis has been previously associated with heart involvement in SSc patients (2), this issue has never been explored among anti-PM/Scl+ patients.Objectives:To evaluate the cardiac involvement in anti-PM/Scl patients with SSc in the large multicentre EUSTAR database, with focus on the subgroup of patients with muscle involvement.Methods:Patients from the EUSTAR database were included when the item anti-PM/Scl was fulfilled in at least one visit.Results:Anti-PM/Scl status was available in 7,353 SSc patients from EUSTAR database: 295 were anti-PM/Scl+. After exclusion of 151 patients with multiple autoantibody positivity, 144 anti-PM/Scl + patients were compared with 7,058 anti-PM/Scl- patients. Among them, 3,120 (44.2%) were positive for ACA, 2,361 (33.5%) for anti-Topo I and 274 (3.88%) for anti-RNAP3.Regarding the specific cardiac outcomes, in the anti-PM/Scl+ as compared to the anti-PM/Scl- group, a decreased rate of elevated sPAP at ECHO was recorded (12.8% vs 25.0%, p:0.001), while no differences were observed in the frequency of conduction blocks (26.2% vs 23.7%, p:0.526), abnormal diastolic function (33.9% vs 36.4%, p:0.582), pericardial effusion (10.2% vs 10.9%, p:1.000) and LVEF ≤50% (4.76% vs 6.11%, p:0.818). In multivariate analysis, adjusted for age at disease onset, sex, and disease duration, the negative association of anti-PM/Scl with elevated sPAP was not confirmed (p:0.061).When comparing anti-PM/Scl+ patients with (n=47) and without (n=87) CK elevation, the former group had a higher frequency of conduction blocks (43.2% vs 17.5%, p:0.005; OR 95% CI 3.47, 1.51-7.97) and left ventricular dysfunction, both diastolic (45.6% vs 27.2%, p:0.050; OR 95% CI 2.25, 1.05-4.81) and systolic (LVEF ≤50% 13.3% vs 0%, p:0.018; OR 95% CI 16.8, 0.87-324). Moreover, anti-PM/Scl+ patients with CK elevation had significantly increased rate of lung fibrosis on HRCT (p:0.045), intestinal symptoms (p:0.017), joint contractures (p:0.045) and tendon friction rubs (p:0.034).Conclusion:In the largest series of anti-PM/Scl positive SSc patients so far reported, muscle involvement in anti-PM/Scl+ patients (defined as increased serum CK) seems to represent a marker of a more severe disease phenotype, including a higher frequency of cardio-pulmonary involvement.References:[1]Lazzaroni MG, et al. Ann Rheum Dis 2018. 77 (2), 421-2.[2]Follansbee WP, et al. Am Heart J 1993. 125: 194-203.Acknowledgments:Authors would like to thank the patients’ association GILS (Gruppo Italiano Lotta Sclerodermia) for the grant that supported the project.Disclosure of Interests:Maria Grazia Lazzaroni: None declared, Stefania Zingarelli: None declared, Paolo Airò: None declared, Yannick Allanore Grant/research support from: BMS, Inventiva, Roche, Sanofi, Consultant of: Actelion, Bayer AG, BMS, BI, Oliver Distler Grant/research support from: Grants/Research support from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd. and Mitsubishi Tanabe; he also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143)., Consultant of: Consultancy fees from Actelion, Acceleron Pharma, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, Catenion, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, iQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi and UCB, Speakers bureau: Speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Pfizer and Roche

Sign in / Sign up

Export Citation Format

Share Document